中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
1期
61
,共1页
邓永红%廖奇%高珊娜%蒋玉凤
鄧永紅%廖奇%高珊娜%蔣玉鳳
산영홍%료기%고산나%장옥봉
新生儿%肺透明膜病%呼吸支持%固尔苏
新生兒%肺透明膜病%呼吸支持%固爾囌
신생인%폐투명막병%호흡지지%고이소
Newborn%Hyaline membrane disease%Respiratory support%Curosurf
目的探讨新生儿肺透明膜病(HMD)呼吸支持治疗的综合诊治,总结并提出新生儿肺透明膜病的呼吸支持治疗的预后措施.方法对本院近2年接收的52例新生儿肺透明膜病的临床诊治进行回顾性分析,把患儿分为固尔苏治疗组和未使用固尔苏治疗两组.52例患儿均进行了对症呼吸支持治疗,供氧治疗,在治疗过程中根据患儿的血氧饱和度、血气检查进行氧气的供给调整.52例患儿中12例进行头罩吸氧,13例患儿进行鼻塞式持续正压通气(CPAP),9例因患儿病情严重无法改善,采用机械通气治疗;7例患儿 X 线片胸部为Ⅲ、Ⅳ级均直接进行了机械通气治疗,11例患儿应用肺泡表面活性药物(PS)固尔苏进行治疗.结果52例新生儿肺透明膜病中治疗痊愈的有31例(78.00%),2例患儿因病情严重恶化放弃治疗(5.66%),7例治疗过程中死亡(16.67%).使用固尔苏治疗的患儿组病死率明显低于未使用固尔苏治疗治疗组(P <0.05),患儿辅助机械通气时间显着缩短(t=2.4252,P <0.01);诊断胸片为Ⅲ、Ⅳ级的改变者较胸片改为Ⅰ、Ⅱ级的机械通气时间长(t=3.7630;P <0.01),病死率高(P <0.01).结论新生儿肺透明膜治病病死率高,应加强孕妇围产期保健;应该肺泡活性药物固尔苏(PS)能有效改善肺透明膜的预后;新生儿体质量大于1800g,胸片改变为Ⅰ、Ⅱ级的新生儿肺透明膜临床诊治综合预后较好,Ⅲ、Ⅳ级预后差.
目的探討新生兒肺透明膜病(HMD)呼吸支持治療的綜閤診治,總結併提齣新生兒肺透明膜病的呼吸支持治療的預後措施.方法對本院近2年接收的52例新生兒肺透明膜病的臨床診治進行迴顧性分析,把患兒分為固爾囌治療組和未使用固爾囌治療兩組.52例患兒均進行瞭對癥呼吸支持治療,供氧治療,在治療過程中根據患兒的血氧飽和度、血氣檢查進行氧氣的供給調整.52例患兒中12例進行頭罩吸氧,13例患兒進行鼻塞式持續正壓通氣(CPAP),9例因患兒病情嚴重無法改善,採用機械通氣治療;7例患兒 X 線片胸部為Ⅲ、Ⅳ級均直接進行瞭機械通氣治療,11例患兒應用肺泡錶麵活性藥物(PS)固爾囌進行治療.結果52例新生兒肺透明膜病中治療痊愈的有31例(78.00%),2例患兒因病情嚴重噁化放棄治療(5.66%),7例治療過程中死亡(16.67%).使用固爾囌治療的患兒組病死率明顯低于未使用固爾囌治療治療組(P <0.05),患兒輔助機械通氣時間顯著縮短(t=2.4252,P <0.01);診斷胸片為Ⅲ、Ⅳ級的改變者較胸片改為Ⅰ、Ⅱ級的機械通氣時間長(t=3.7630;P <0.01),病死率高(P <0.01).結論新生兒肺透明膜治病病死率高,應加彊孕婦圍產期保健;應該肺泡活性藥物固爾囌(PS)能有效改善肺透明膜的預後;新生兒體質量大于1800g,胸片改變為Ⅰ、Ⅱ級的新生兒肺透明膜臨床診治綜閤預後較好,Ⅲ、Ⅳ級預後差.
목적탐토신생인폐투명막병(HMD)호흡지지치료적종합진치,총결병제출신생인폐투명막병적호흡지지치료적예후조시.방법대본원근2년접수적52례신생인폐투명막병적림상진치진행회고성분석,파환인분위고이소치료조화미사용고이소치료량조.52례환인균진행료대증호흡지지치료,공양치료,재치료과정중근거환인적혈양포화도、혈기검사진행양기적공급조정.52례환인중12례진행두조흡양,13례환인진행비새식지속정압통기(CPAP),9례인환인병정엄중무법개선,채용궤계통기치료;7례환인 X 선편흉부위Ⅲ、Ⅳ급균직접진행료궤계통기치료,11례환인응용폐포표면활성약물(PS)고이소진행치료.결과52례신생인폐투명막병중치료전유적유31례(78.00%),2례환인인병정엄중악화방기치료(5.66%),7례치료과정중사망(16.67%).사용고이소치료적환인조병사솔명현저우미사용고이소치료치료조(P <0.05),환인보조궤계통기시간현착축단(t=2.4252,P <0.01);진단흉편위Ⅲ、Ⅳ급적개변자교흉편개위Ⅰ、Ⅱ급적궤계통기시간장(t=3.7630;P <0.01),병사솔고(P <0.01).결론신생인폐투명막치병병사솔고,응가강잉부위산기보건;응해폐포활성약물고이소(PS)능유효개선폐투명막적예후;신생인체질량대우1800g,흉편개변위Ⅰ、Ⅱ급적신생인폐투명막림상진치종합예후교호,Ⅲ、Ⅳ급예후차.
Objective Explored the comprehensive diagnosis and treatment of hyaline membrane disease(HMD) respiratory support treatment,summarized the neonatal measures of HMD respiratory support treatment. Methods Retrospectively analyzed 52 cases with HMD in our hospital for nearly 2 years, divided into the Curosurf group and no use Curosurf group.all 52 cases with symptomatic respiratory support treatment, oxygen treatment,during treatment of children with oxygen saturation, blood gas to check the oxygen supply. Results Cured in 52 cases of HMD in 31 cases(78.00%),2 cases with serious deterioration so gave up treatment(5.66%),7 cases during the treatment died(16.67%). Curosurf children mortality rate was significantly lower than the unused Curosurf treatment group (P<0.05), children assisted mechanical ventilation time was significantly shortened (t = 2.4252, P <0.01); diagnostic chest X-rayfor Ⅲ of grade Ⅳ change compared to chest X-ray instead Ⅰ class II mechanical ventilation time (t = 3.7630; P <0.01), and high mortality (P <0.01).Conclusion HMD had high mortality,should strengthen the perinatal care of pregnant women; alveolar active drug Curosurf(PS)can effectively improve the prognosis of HMD;birth weight than 1800g, HMD chest X-ray changed in grade I、II had a good clinical diagnosis and treatment prognosis,grade III、IV was poor.